查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403480

到 2030 年癌症切片检查市场预测：按产品、类型、应用、最终用户和地区进行的全球分析

Cancer Biopsy Market Forecasts to 2030 - Global Analysis By, Product (Instruments, Kits and Consumables and Other Products), Type (Tissue Biopsies, Liquid Biopsies, Surgical Biopsies and Other Types), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球癌症切片检查市场规模为 266 亿美元，预计在预测期内将以 20% 的复合年增长率增长，到 2030 年达到 954 亿美元。

癌症切片检查是一种医疗程序，从可疑或异常的生长、肿块或病变中取出小组织样本并进行检查，以确定癌细胞的存在、性质和特征。癌症切片检查为肿瘤学家和医疗保健专业人员提供准确、详细的资讯，以便根据每个患者的癌症特征做出准确的诊断并製定量身定制的治疗计划。这是有帮助的基本内容。

根据美国乳癌统计数据，美国大约八分之一的女性患有侵袭性乳癌。

癌症发生率上升

癌症仍然是一个全球性的健康问题，由于高龄化、生活方式改变、环境暴露和遗传倾向等多种因素，越来越多的人被诊断出患有各种类型的癌症。随着癌症患者数量的增加，对准确、及时的癌症诊断的需求也随之增加。切片检查程序透过取出组织样本进行病理分析，在确认癌症诊断方面发挥重要作用。因此，癌症发生率上升是加速市场需求的关键因素。

高成本

高诊断成本是预计抑制全球癌症切片检查市场成长的主要因素之一。癌症诊断测试​​价格高成本，给患者家庭带来额外的经济负担。因此，这些测试对于没有保险的中产阶级患者群体来说是遥不可及的。此外，高昂的诊断成本限制了癌症筛检技术的使用，因为许多私人公司不支付与癌症诊断相关的费用。

技术进步

技术进步导致了微创切片检查技术的发展，例如细针抽吸（FNA）、核心切片检查（CNB）和内视镜切片检查。与传统的开放性手术相比，这些手术使用较小的切口和针头来获取组织样本，减少患者不适，最大限度地降低併发症的风险，并提高康復速度。这些因素正在推动市场需求。

缺乏意识

在某些地区和人群中，一般民众和医疗保健专业人员对切片检查在癌症诊断中的重要角色认识不足。患者可能不完全理解切片检查程序在确定肿瘤的性质和特征方面的重要性，并且可能会犹豫或不愿意接受此类必要的诊断测试。因此，缺乏认识是市场的主要抑制因素。

COVID-19 的影响

COVID-19 的出现对癌症切片检查市场产生了重大影响。疫情阶段，由于社交距离措施，医院就诊受到严格限制，只允许急诊病患入院，对市场扩张产生了负面影响。此外，在疫情大流行之后，新技术的采用有所增加，为所研究的市场开闢了新的前景。

预计切片检查部分在预测期内将是最大的

手术切片检查领域估计占据最大份额。外科切片检查涉及在切口或外科手术过程中取出组织样本。当需要大的组织标本进行进一步检查时，通常会采用这种方法，以便病理学家分析肿瘤的​​特征、恶性和范围。对于癌症切片检查，手术切片检查经常用于位于深部或难以接近位置的肿瘤，在这些位置获取足够的组织标本对于准确的诊断和治疗计划非常重要。

预计设备领域在预测期内将呈现最高的复合年增长率。

预计家电领域在预测期内将出现良好的成长。设备在促进准确有效的切片检查程序以及有助于准确的癌症诊断和治疗决策方面发挥着至关重要的作用。这些仪器包括用于获取组织样本进行测试的各种仪器，包括传统的切片穿刺针、切片检查钳以及专为微创手术设计的专用仪器。此外，超音波、MRI和CT扫描仪等先进的影像设备对于引导临床医生到特定部位进行切片检查并提供有针对性和准确的采样至关重要。

占比最大的地区：

由于医疗保健基础设施的快速进步以及对癌症早期检测和治疗的兴趣日益浓厚，亚太地区在预测期内占据了最大的市场占有率。在中国、印度和日本等国家，癌症患者的盛行率不断增加，这增加了对切片检查作为诊断途径关键组成部分的需求。此外，该地区致力于改善癌症治疗和促进医学研究，并在全球癌症切片检查市场中发挥关键作用。

复合年增长率最高的地区：

由于先进的医疗基础设施、癌症患者的高盛行率以及对技术创新的积极关注，预计北美在预测期内将出现有益的成长。在北美，广泛采用各种切片检查技术，包括手术切片检查、针吸活检和液体活检，以获得准确、全面的资讯，用于癌症诊断和治疗计划。此外，尖端影像技术、分子诊断和微创切片检查方法的采用凸显了该地区对提高诊断准确性和患者治疗结果的承诺。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球癌症切片检查市场：副产品

  • 装置
  • 套件/消耗品
  • 其他产品

第六章全球癌症切片检查市场：按类型

  • 组织切片检查
    • 针吸切片
      • 细针抽吸
      • 空心针活检
    • 手术切片检查
  • 液体活检
  • 手术切片检查
  • 其他类型

第七章全球癌症切片检查市场：依应用分类

  • 子宫颈癌
  • 大肠直肠癌
  • 摄护腺癌
  • 乳癌
  • 肺癌
  • 皮肤癌
  • 肾癌
  • 血癌
  • 卵巢癌
  • 肝癌
  • 胰臟癌
  • 其他用途

第八章全球癌症切片检查市场：按最终用户分类

  • 诊断实验室
  • 医院
  • 其他最终用户

第九章全球癌症切片检查市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Becton, Dickinson and Company
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Hologic, Inc.
  • NeoGenomics, Inc.
  • Koninklijke Philips NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Sysmex Corporation
Product Code: SMRC24705

According to Stratistics MRC, the Global Cancer Biopsy Market is accounted for $26.6 billion in 2023 and is expected to reach $95.4 billion by 2030 growing at a CAGR of 20% during the forecast period. A cancer biopsy is a medical procedure involving the removal and examination of a small tissue sample from a suspicious or abnormal growth, lump, or lesion to determine the presence, nature, and characteristics of cancer cells. Cancer biopsies are fundamental to providing accurate and detailed information for oncologists and healthcare professionals, helping them formulate precise diagnoses and develop tailored treatment plans based on the unique characteristics of each patient's cancer.

According to USA breast cancer statistics, about one in every eight women in the USA develops invasive breast cancer.

Market Dynamics:

Driver:

Rising cancer incidence

Cancer continues to be a global health concern, with increasing numbers of individuals being diagnosed with various types of cancer due to various factors such as aging populations, lifestyle changes, environmental exposures, and genetic predisposition. As the number of cancer cases increases, the demand for accurate and timely cancer diagnosis also grows. Biopsy procedures play a crucial role in confirming cancer diagnoses by obtaining tissue samples for pathological analysis. Therefore, rising cancer incidence is a significant factor accelerating market demand.

Restraint:

High cost

The high cost of diagnosis is one of the main factors anticipated to impede the growth of the global cancer biopsy market. Cancer diagnostic tests are highly costly, which puts additional financial strain on patient families. Thus, these tests are not affordable for middle-class patient population that is not covered under any insurance. Additionally, a number of private insurance companies do not pay for cancer diagnosis-related expenses, which means that the high cost of diagnosis restricts the use of cancer screening technologies.

Opportunity:

Technological advancements

Technological advancements have led to the development of minimally invasive biopsy techniques such as fine needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsy. These techniques use smaller incisions or needles to obtain tissue samples, reducing patient discomfort, minimizing the risk of complications, and enabling faster recovery compared to traditional open surgical biopsies. These factors enhance market demand.

Threat:

Lack of awareness

In certain regions or demographic segments, there is a lack of sufficient awareness among both the general population and healthcare professionals about the critical role of biopsies in cancer diagnosis. Patients may not fully comprehend the importance of biopsy procedures in determining the nature and characteristics of tumours, leading to hesitancy or reluctance to undergo these essential diagnostic tests. As a result, a lack of awareness is a significant restraint hampering the market.

COVID-19 Impact

The emergence of COVID-19 had a significant impact on the cancer biopsy market. Hospital visits were severely restricted during the early stages of the pandemic as a result of social distancing measures; only patients with emergencies were permitted, which had a negative effect on the market's expansion. Moreover, following the pandemic, there was a rise in the adoption of new technologies, which opened up new prospects for the market under study.

The surgical biopsies segment is expected to be the largest during the forecast period

The surgical biopsies segment is estimated to hold the largest share. A surgical biopsy involves the removal of a tissue sample through an incision or during a surgical procedure. This method is commonly employed when larger tissue specimens are needed for thorough examination, allowing pathologists to analyze the tumour's characteristics, grade, and extent of spread. In cancer biopsies, surgical biopsies are frequently utilized for tumours located in deep or challenging-to-access areas, where obtaining an adequate tissue sample is crucial for accurate diagnosis and treatment planning.

The instruments segment is expected to have the highest CAGR during the forecast period

The instruments segment is anticipated to have lucrative growth during the forecast period. Instruments play a pivotal role in facilitating precise and effective biopsy procedures, contributing to accurate cancer diagnoses and treatment decisions. These instruments encompass a wide range of devices used to obtain tissue samples for examination, including traditional biopsy needles, biopsy forceps, and specialized tools designed for minimally invasive procedures. Additionally, advanced imaging instruments such as ultrasound, MRI, and CT scanners are integral to guiding clinicians to the specific site for biopsy, ensuring targeted and accurate sampling.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to rapid advancements in healthcare infrastructure and a growing focus on early cancer detection and treatment. With a rising prevalence of cancer cases in countries like China, India, and Japan, there is an increasing demand for biopsy procedures as a crucial component of the diagnostic pathway. Moreover, the region's commitment to improving cancer care and fostering medical research positions it as a key contributor to the global cancer biopsy market.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to advanced healthcare infrastructure, a high prevalence of cancer cases, and a robust focus on technological innovation. In North America, various biopsy techniques, including surgical, needle, and liquid biopsies, are widely employed to obtain precise and comprehensive information for cancer diagnosis and treatment planning. Additionally, the adoption of cutting-edge imaging technologies, molecular diagnostics, and minimally invasive biopsy procedures underscores the region's commitment to enhancing diagnostic accuracy and patient outcomes.

Key players in the market:

Some of the key players in the Cancer Biopsy Market include Becton, Dickinson and Company, Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Illumina, Inc., Myriad Genetics, Inc., Hologic, Inc., Neo Genomics, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc., QIAGEN N.V. and Sysmex Corporation.

Key Developments:

In May 2023, Partnership between Thermo Fisher Scientific and BRIN to enable and enhance the country's national research and innovation infrastructure and capability.

In March 2023, Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.

In Jan 2023, Philips a global leader in health technology, and Masimo, a global medical technology company, announced an expansion of their partnership to augment patient monitoring capabilities in home telehealth applications with the Masimo W1™ advanced health tracking watch.

Products Covered:

  • Instruments
  • Kits and Consumables
  • Other Products

Types Covered:

  • Tissue Biopsies
  • Liquid Biopsies
  • Surgical Biopsies
  • Other Types

Applications Covered:

  • Cervical Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Skin Cancer
  • Kidney Cancer
  • Blood Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Other Applications

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Biopsy Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Kits and Consumables
  • 5.4 Other Products

6 Global Cancer Biopsy Market, By Type

  • 6.1 Introduction
  • 6.2 Tissue Biopsies
    • 6.2.1 Needle Biopsies
      • 6.2.1.1 Fine Needle Aspiration
      • 6.2.1.2 Core Needle Biopsy
    • 6.2.2 Surgical Biopsies
  • 6.3 Liquid Biopsies
  • 6.4 Surgical Biopsies
  • 6.5 Other Types

7 Global Cancer Biopsy Market, By Application

  • 7.1 Introduction
  • 7.2 Cervical Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Prostate Cancer
  • 7.5 Breast Cancer
  • 7.6 Lung Cancer
  • 7.7 Skin Cancer
  • 7.8 Kidney Cancer
  • 7.9 Blood Cancer
  • 7.10 Ovarian Cancer
  • 7.11 Liver Cancer
  • 7.12 Pancreatic Cancer
  • 7.13 Other Applications

8 Global Cancer Biopsy Market, By End User

  • 8.1 Introduction
  • 8.2 Diagnostic Laboratories
  • 8.3 Hospitals
  • 8.4 Other End Users

9 Global Cancer Biopsy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Becton, Dickinson and Company
  • 11.2 Abbott Laboratories
  • 11.3 Danaher Corporation
  • 11.4 F. Hoffmann-La Roche Ltd.
  • 11.5 Bio-Rad Laboratories, Inc.
  • 11.6 Illumina, Inc.
  • 11.7 Myriad Genetics, Inc.
  • 11.8 Hologic, Inc.
  • 11.9 NeoGenomics, Inc.
  • 11.10 Koninklijke Philips N.V.
  • 11.11 Siemens Healthineers AG
  • 11.12 Thermo Fisher Scientific Inc.
  • 11.13 QIAGEN N.V.
  • 11.14 Sysmex Corporation

List of Tables

  • Table 1 Global Cancer Biopsy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cancer Biopsy Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Cancer Biopsy Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 4 Global Cancer Biopsy Market Outlook, By Kits and Consumables (2021-2030) ($MN)
  • Table 5 Global Cancer Biopsy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 6 Global Cancer Biopsy Market Outlook, By Type (2021-2030) ($MN)
  • Table 7 Global Cancer Biopsy Market Outlook, By Tissue Biopsies (2021-2030) ($MN)
  • Table 8 Global Cancer Biopsy Market Outlook, By Needle Biopsies (2021-2030) ($MN)
  • Table 9 Global Cancer Biopsy Market Outlook, By Surgical Biopsies (2021-2030) ($MN)
  • Table 10 Global Cancer Biopsy Market Outlook, By Liquid Biopsies (2021-2030) ($MN)
  • Table 11 Global Cancer Biopsy Market Outlook, By Surgical Biopsies (2021-2030) ($MN)
  • Table 12 Global Cancer Biopsy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 13 Global Cancer Biopsy Market Outlook, By Application (2021-2030) ($MN)
  • Table 14 Global Cancer Biopsy Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 15 Global Cancer Biopsy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 16 Global Cancer Biopsy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 17 Global Cancer Biopsy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 18 Global Cancer Biopsy Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 19 Global Cancer Biopsy Market Outlook, By Skin Cancer (2021-2030) ($MN)
  • Table 20 Global Cancer Biopsy Market Outlook, By Kidney Cancer (2021-2030) ($MN)
  • Table 21 Global Cancer Biopsy Market Outlook, By Blood Cancer (2021-2030) ($MN)
  • Table 22 Global Cancer Biopsy Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 23 Global Cancer Biopsy Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 24 Global Cancer Biopsy Market Outlook, By Pancreatic Cancer (2021-2030) ($MN)
  • Table 25 Global Cancer Biopsy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 26 Global Cancer Biopsy Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Cancer Biopsy Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 28 Global Cancer Biopsy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Cancer Biopsy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.